Squalestatin 1
Alternative Names: Zaragozic acid ALatest Information Update: 18 May 1995
At a glance
- Originator GlaxoSmithKline; Merck & Co
- Developer GlaxoSmithKline
- Class Antifungals; Antihyperlipidaemics
- Mechanism of Action Squalene synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 18 May 1995 Discontinued-Preclinical for Hyperlipidaemia in United Kingdom (Unknown route)